Science

Pipeline
We are focused on the rapid design and development of precision therapies for people with cancer and rare diseases.
Assets
Target
Indication
Mono/Combo
Discovery
IND Enabling
Phase l/la
POC (i)
Pivotal
Partner
Abbisko Rights
ABSK021 Pimicotinib
CSF-1R
TGCT
Monotherapy

Ex-Greater China

ABSK021 Pimicotinib
CSF-1R
cGvHD
Monotherapy

Ex-Greater China

ABSK021 Pimicotinib
CSF-1R
Solid tumors
Monotherapy/
Combination therapy

Ex-Greater China

ABSK011 Irpagratinib
FGFR4
FGF19+HCC
Monotherapy

Global

ABSK011 Irpagratinib
FGFR4
FGF19+HCC
Combination therapy(ii)

Global

ABSK091 Fexagratinib
pan-FGFR
FGFRalt UC
Monotherapy
Partner

Global

ABSK091 Fexagratinib
pan-FGFR
FGFRalt UC
Combination therapy(iv)

Global

ABSK091 Fexagratinib
pan-FGFR
Other solid tumors
Monotherapy

Global

ABSK061
FGFR2/3 selective
Solid tumors
Monotherapy

Global

ABSK121
pan-FGFR mut.
Solid tumors
Monotherapy

Global

ABSK112
EGFR Exon20
NSCLC
Monotherapy

Global

ABSK043
PD-L1 (Oral)
Multiple tumors
Monotherapy

Global

ABSK081
CXCR4
TNBC
Combination therapy(iii)

Greater China
Commerical Rights

ABSK081
CXCR4
WHIM
Monotherapy
Partner

Greater China
Commerical Rights

ABSK051
CD73
Multiple tumors
Monotherapy

Global

ABSK012
FGFR4 mut.
RMS and other
Solid tumors
Monotherapy

Global

ABK3376
EGFR-C797S
EGFRm NSCLC
Monotherapy/
Combination therapy

Ex-Greater China

ABSK071
KRAS
Solid tumors
Monotherapy

Global

P131
MTA cooperative PRMT5
Multiple tumors
Monotherapy

Global

P141
Undisclosed
Multiple tumors
Monotherapy

Global

P151
Undisclosed
Non-oncology
Monotherapy

Shared

Abbreviations: HCC = hepatocellular carcinoma; RMS = rhabdomyosarcoma; FGFRalt = FGFR altered; UC = urothelial cancer; NSCLC = non-small cell lung cancer; TGCT = tenosynovial giant cell tumor; cGvHD = chronic graft- versus-host disease; ALS = amyotrophic lateral sclerosis; TNBC = triple-negative breast cancer; WHIM = warts, hypogammaglobulinemia, infections and myelokathexis i. Represents Phase Ib/II clinical trial ii. In combination with anti-PD-L1 antibody atezolizumab with Roche iii. In combination with anti-PD-1 antibody toripalimab with Junshi iv. In combination with anti-PD-1 antibody tislelizumab with Beigene

Tel:(+86) 021-68912098

E-Mail:Bd@abbisko.com
    PR@abbisko.com
    IR@abbisko.com

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号-1